Reuters logo
BRIEF-Hybrigenics' compound inhibits USP10 and shows activity in preclinical models of AML
October 9, 2017 / 6:30 PM / 11 days ago

BRIEF-Hybrigenics' compound inhibits USP10 and shows activity in preclinical models of AML

Oct 9 (Reuters) - HYBRIGENICS SA:

* HYBRIGENICS’ COMPOUND INHIBITS UBIQITIN-SPECIFIC PROTEASE 10 (USP10) AND SHOWS ACTIVITY IN PRECLINICAL MODELS OF ACUTE MYELOID LEUKEMIA‍​

* PUBLICATION IN “NATURE CHEMICAL BIOLOGY” IDENTIFIES USP10 “AS A CRITICAL EFFECTOR ENZYME OF TUMOR GROWTH AND SURVIVAL IN SUBJECTS WITH FLT3-MUTATED AML

* PUBLICATION REPORTS “THE TOP HIT FROM OUR SCREEN, HBX 19,818, LED TO STRIKING AND SELECTIVE ANTIPROLIFERATIVE EFFECTS AGAINST MUTANT-FLT3-POSITIVE AML CELLS” Source text: bit.ly/2xubfFL Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below